In this review we propose an integrated neuro-endocrine-metabolic point of view on the alterations (adaptations?) of GHaIGF-1 axis in obesity, summarizing the evidence from the literature, particularly focusing the data on humans and adding where possible results from our studies in this ®eld. It is well-known that GH secretion is deeply impaired in overweight patients: we reviewed the multiple mechanisms underlying this issue, considering either central (CNS-related, such as impairment of GHRH tone or increased somatostatin release) or peripheral (ie metabolic: insulin, free fatty acids, glucose) factors. A central point of the debate about GH insuf®ciency in obesity is if it represents a simple adaptive phenomenon or re¯ects a true impairment of the axis activity. Evaluation of IGF-I levels and generation in obesity was the mean used to address this question: a bulk of evidence on IGF-I balance in human obesity has been provided, but the matter is still uncertain and unsolved.
Introduction
It is widely accepted that the activity of growth hormoneainsulin growth factor I (GHaIGF-I) axis is devoted to promoting growth as well as to controling metabolism, structure functions and body composition. Its activity is mainly under neuro-endocrine control, but the metabolic in¯uences on its function have critical importance. In fact, age, sex and adiposity are the major determinants of growth hormone (GH) secretion in humans. 1 Thus, among endocrine changes in obesity, the alteration of the GHaIGF-I axis seems of particular interest because its understanding requires an approach in which neuroendocrinology and metabolism are tightly linked. The recent studies on leptin, a peptidyl hormone from adipocytes which plays a critical role in the metabolic control via the CNS, is the best example of this assumption. In fact, in this paper we will not focus on the role of leptin in the control of GHaIGF-I axis; this topic will be discussed extensively in the paper from C Dieguez and FF Casanueva in this issue.
Somatotroph secretion in obesity
It has been clearly shown that GH secretion is negatively and independently associated with age and adiposity in normal subjects. 1 Thus it is not surprising that circulating GH levels are reduced in obesity.
Reduced GH half-life does not fully explain reduced GH levels, which re¯ect the true reduction of 24 h GH production rate; 2 thus obesity is a real condition of GH insuf®ciency.
Besides low spontaneous GH secretion, a clear reduction of the somatotroph response to all known stimuli has been clearly demonstrated in obese patients. In fact, approximately 40 ± 70% reduction of the GH response to all known stimuli, 3 ± 14 including GHRH both alone 11 and combined with pyridostigmine (PD) or arginine (ARG) 12, 13 and GH secretagogues (GHRPs), 14 the most potent stimuli of GH secretion known so far.
The general assumption is that somatotroph insuf®ciency in obesity is reversible after weight loss.
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Norma1ization of spontaneous GH secretion after long-term diet-induced weight loss has been reported in obese patients. 15 Moreover, it has been reported that even short-term fasting enhances the GH response to GHRH as well as long term diet; 16 however, the fasting-induced increase of the GH response to GHRH in controls persisted higher than that recorded in obese patients. 16 In our experience, fasting does not restore all the somatotroph secretion in obesity. In fact, unlike lean controls, 8 h mean GH concentration was not signi®cantly enhanced by 36 h fasting and was similar to that in hypopituitaric patients with severe GHD in whom, as expected, fasting was unable to increase GM levels (personal,unpublished data). Moreover we have previously shown that 3 day fasting is unable to modify the GH response to GHRH both alone and combined with ARG in obese patients, in whom the GH response was markedly lower than that in lean controls. 17 More recently we have studied the effect of gastroplasty-induced massive weight loss (approximately 30%) on the GH response to GHRH alone and combined with ARG in obese patients, which showed no change of IGF-I levels. Indeed, massive weight loss enhanced the GH response to GHRH alone and much more than to GHRH ARG; however these responses were lower than that in lean controls, and similar to that in another group of obese patients of similar BMI (personal unpublished results). These results suggest that full BMI normalization is probably needed to fully restore somatotroph secretion, but this is rarely achieved.
In this context, it has to be emphasized that there are data showing that genetically obese rats have normal GH content per somatotroph cell, but the total number of somatotroph cells is reduced. Thus genetically obese rats have low total GH content in the pituitary and this feature is present in animals even before the development of overweight. 18 Moreover, clear reduction of GH synthesis has also been shown in overfed obese rats 19 and this evidence further suggests the hypothesis that somatotroph defect in obesity could be functional and easily reversible by weight loss.
Concerning the pathogenesis of GH insuf®ciency in obesity, the following hypothetical causes have to be taken into account: (a) somatotroph defect primary or secondary to; (b) hypothalamic alterations such as somatostatinergic hyperactivity, GHRH hypoactivity, hypoactivity of the endogenous GHRP-like ligand, enhanced negative IGF-I feedback; and (c) metabolic alterations such as hyperinsulinism and elevated free fatty acids (FFA). As alluded to in the Introduction, alterations in the NPYaleptin interplay could also play a critical role (see Dieguez et al in this issue).
Among hypothetical hypothalamic alterations, the existence of hypothalamic somatostatinergic hyperactivity, previously observed in genetically obese rats, 20 is unlikely to occur in human obesity, based on our indirect evidence that PD or ARG, which probably act via inhibition of hypothalamic SS, increase but never restore the GH response to GHRH in obese patients. 8, 13 More recently, it has been clearly demonstrated that hypothalamic SS is not increased in obese rats which show reduced pituitary GH content as well as low hypothalamic GHRH content. 21 In humans, we have found that 8 day GHRH pretreatment enhanced the low GH response to GHRH in elderly subjects but did not affect that in obese patients. 22 These ®ndings, however, do not de®nitively rule out the possibility that endogenous GHRH hypoactivity plays a critical role.
The hypothetical hypoactivity of the putative endogenous GHRP-like ligand is unlikely; in fact, GHRPs, particularly when combined with GHRH elicit massive GH release in obese patients but even this response is still lower than that in lean controls. 14 Concerning the role of metabolic alterations, obesity is associated with elevated FFA levels which are known to have an inhibitory effect on somatotroph secretion. This is also indicated by evidence that lipidheparin infusion leading to clearcut increase of circulating FFA levels abolishes the GH response to GHRH and also blunts that to GHRPs in normal subjects. 23 Indeed, short and much more long term treatment with acipimox, a lypolysis inhibitor in obese patients restores the GH response to several stimuli including GHRH alone and combined with ARO or GHRPs. 24 ± 26 Thus elevated FFA levels probably play the most important role in the pathogenesis of GH insuf®ciency in obesity. FFA action does not seem to be exerted at the hypothalamic level and very likely takes place directly at the pituitary levels as inhibition of somatotroph cell membrane depolarization. 27 However, chronic inhibition of lypolysis is also able to reduce insulin levels and improve insulin sensitivity in obesity 28 and insulin is, in turn, able to directly inhibit GH synthesis and release from somatotroph cells 29 as well as to reduce the GH response to hypoglycemic clamp in normal subjects. 30 Thus, hyperinsulinism could also play a role in the pathogenesis of GH insuf®ciency in obesity.
Obese patients even show altered sensitivity to glucose variations. In fact, refractoriness to the inhibitory effect of OGTT-induced hyperglycemia on the GH response to GHRH, arginine and GHRPs has been shown in obesity, 31, 32 in which late stimulatory effect of hyperglycemia on GH secretion is present, albeit reduced. 33 The peculiar loss of the CNS-mediated inhibitory effect of hyperglycemia on somatotroph secretion in obesity could re¯ect refractoriness of hypothalamic SS neurons to hyperglycemia; this could, in turn, re¯ect the negative effect of hyperinsulism on glucose uptake in hypothalamic neurons reported in experimental animals. 34 Basically these ®ndings point toward some hypothalamic insensitivity to glucose variations in obesity.
IGF-I secretion in obesity
Total IGF-I levels in obesity have been reported to be increased, normal or decreased. 35 ± 38 In our experience, in a large population of the obese we found a slight reduction in mean IGF-I levels which reached statistical signi®cance in the fourth decade of life only, with individual IGF-I levels generally within age-related normative values of IGF-I (personal unpublished data). Thus mean total IGF-I levels in obesity are only slightly reduced in spite of marked GH insuf®ciency.
Indeed, total IGF-I levels have been found to be negatively associated with visceral adiposity 38 and recently it has been reported that overweight patients with metabolic syndrome X bene®t from treatment with recombinant human GH (rhGH) leading to increase of IGF-I levels. 39 This approach is based on evidence that hypopituitaric patients with severe GHD have metabolic features which are reversed by GH replacement and are very close to those in metabolic syndrome X.
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Attention should be given, however, to recent data that show, differently from total IGF-I levels, that free IGF-I levels have been found to be increased in obese patients, 35 questioning the existence of hypoactivity of GHaIGF-I axis and therapeutic approaches devoted to further increasing IGF-I levels by rhGH administration.
Elevated free IGF-I levels in obesity can be explained on a rational basis. IGF-I synthesis and secretion depend on peripheral GH sensitivity which is re¯ected by GH receptor (GHR) and GH binding protein (GHBP) levels which have been reported to be increased in obese patients. 40 Hyperinsulinism could enhance the peripheral sensitivity to GH and reduce IGFBP-l levels; 41 thus hyperinsulism could explain almost normal total IGF-I levels and increased free IGF-I levels which, in turn, could exert an increased negative feedback action on somatotroph cells.
Interestingly, personal unpublished results in obese patients do not con®rm the existence of enhanced peripheral GH sensitivity. In fact, the IGF-I response to very low rhGH dose in obese patients elicited an IGF-I response similar to that in normal controls but had poorer peripheral insulin sensitivity.
Conclusions
At present it is still unclear if the changes in the activity of GHaIGF-I axis in obesity are alterations or adaptations. Indeed obese patients show marked GH insuf®ciency, but IGF-I activity is mostly preserved. Several neuroendocrine and metabolic alterations play a critical role in determining this picture and it is probably impossible to distinguish in this tight interplay a factor as ®rst cause or consequence. The activity of GHaIGF-I axis could be only reset and balanced as a response to the condition of obesity.
